BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28128743)

  • 1. The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.
    Chen E; Zheng F; Yuan X; Ye Y; Li X; Dai Y; Chen L
    Cancer Biomark; 2017; 19(2):207-212. PubMed ID: 28128743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
    Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.
    Lee SM; Park JY; Kim DS
    Mol Cells; 2012 Aug; 34(2):171-6. PubMed ID: 22814847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.
    Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M
    Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTERT promoter methylation and single nucleotide polymorphism (-245 T>C) affect renal cell carcinoma behavior in Serbian population.
    Trifunovic J; Basta Jovanovic G; Nikolic N; Carkic J; Marjanovic A; Brankovic M; Radojevic Skodric S; Prvanovic M; Jovanovic A; Dzamic Z; Milasin J
    J BUON; 2018; 23(6):1887-1892. PubMed ID: 30610818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
    Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
    Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
    Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 14. Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma.
    Kang HW; Park H; Seo SP; Byun YJ; Piao XM; Kim SM; Kim WT; Yun SJ; Jang W; Shon HS; Ryu KH; Lee SC; Kim WJ; Kim YJ
    J Korean Med Sci; 2019 May; 34(19):e144. PubMed ID: 31099194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
    Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P; Ye L; Yang Y; Jiang WG
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
    Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer-retina antigen recoverin as a potential biomarker for renal tumors.
    Golovastova MO; Tsoy LV; Bocharnikova AV; Korolev DO; Gancharova OS; Alekseeva EA; Kuznetsova EB; Savvateeva LV; Skorikova EE; Strelnikov VV; Varshavsky VA; Vinarov AZ; Nikolenko VN; Glybochko PV; Zernii EY; Zamyatnin AA; Bazhin AV; Philippov PP
    Tumour Biol; 2016 Jul; 37(7):9899-907. PubMed ID: 26813565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of
    Zheng F; Yuan X; Chen E; Ye Y; Li X; Dai Y
    Oncol Lett; 2017 Sep; 14(3):3065-3070. PubMed ID: 28927054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.